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1. Introduction  
Traditional folk medicine makes good use of the flora and fauna of a region, including a 
number of mineral substances. These herbs and animals are used either whole or in part and 
made up in either simple or complicated preparations and have proved to be effective 
therapeutic remedies. Some of these medicinal substances of animal origin have been quite 
thoroughly studied with modern scientific methods, and their therapeutic properties have 
been confirmed although not always explained. Many others have yet to be subjected to 
scientific analysis and tests before their real value can be judged. Products of animal origin 
despite of their therapeutic values have been banned in many countries for the sake of 
sustainable development in addition to safeguard ecological balance.  
It is known from traditional folk knowledge that the placenta, supporting the baby's growth 
and development in the mother’s womb, contains a wide range of biologically active 
components. Research over decades has been uncovering more and more of these 
compounds. Indeed, it is claimed that the placenta is capable of producing just about any 
substance found in any organ of the body. This biochemical treasure house supplies the 
growing fetus with substances that the fetus itself cannot synthesize. Though a rich source 
of bioactive components unless recovered, placenta becomes a biomedical waste 
immediately after childbirth.  Use of human placenta as a therapeutic agent, therefore, in no 
way hampers ecological balance rather promotes resource recovery from a designated 
biomedical waste. Since most of the natural products of medicinal value have a vast 
repertoire of potent biological components, there has been an increasing realization to shun 
synthetic and semi-synthetic medicines primarily because of their harmful side effects.  
Research on human placental extract gained a momentum with the description of the 
preparation of its extract by Russian ophthalmologist Prof. V.P. Filatov. Prior to his research, 
there were no documents of therapeutic efficacy of the extract, though its use was popular in 
Europe and parts of Asia primarily China, Korea and Japan for over a century. Review of 
placenta therapy reveals its long usage from the days of distant past. Recent medical history 
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from 1912 showed that Filatov started research on grafting human corneas using the principle 
of transplantation of preserved material. He observed that when animal or vegetable tissues 
are isolated from the organism and subjected to the action of environmental factors that inhibit 
their vital processes, they undergo a biochemical readjustment. In consequence to this 
readjustment, the tissues develop substances that stimulate their vital processes. Filatov 
named these substances as Biogenic stimulators (Filatov, 1951). After many clinical experiments, 
Filatov was convinced that any tissue of human or animal origin could be used to obtain 
curative effect and this tissue may not necessarily correspond histologically to the tissue 
affected by the pathological process. He extended this principle to general medicine and 
confirmed that the process was just as valid for other human tissues. That is how the principle 
of therapeutic tissue was born (Filatov, 1955).  
Placenta serves as a natural storehouse of many biologically active components with 
significant healing attributes (Tonello et al., 1996). Various extracts of placenta have been 
described, however, only an aqueous extract of fresh full term human placenta acts as a 
potent biogenous stimulator (Wu et al., 2003). Over a period of time, it has been 
demonstrated that only an aqueous extract of human placenta has effective therapeutic 
potential. The composition of the extracts depends on the method of its preparation and 
consequently, they show different therapeutic activities. Clinical efficacy of an aqueous 
extract of human placenta in wound healing is already established (Hong et al, 2010, Wu et 
al., 2003). Globally scientists are investigating on placenta as a total organ and they expect to 
discover new applications exploiting the potency of the organ and identify new compounds 
in near future. This aqueous extract finds importance owing to its ability in curing chronic 
non-healing wounds including post-surgical dressings and high degree of burn injuries (Wu 
et al., 2003).   
Wound healing is a complicated interrelated process wherein the injured dermal and 
epidermal tissue is naturally regenerated. Though well regulated, the process of healing is 
susceptible to interruption or failure leading to the formation of chronic non-healing 
wounds. Factors which may contribute to this include diabetes, venous or arterial disease, 
old age and infection. Placental extract, ever since its usage has been shown to be clinically 
effective in healing normal as well as infected wounds (Shukla et al., 2004, Chakraborty et 
al., 2009). It is involved in almost every stage of healing. It is also used in wound dressings 
to speed up the process of recovery. Though clinically well-tested, emphasis is now being 
laid in understanding the bioactive components involved in the process of healing. Research 
on the extract has highlighted some important components that might play roles in this 
process while few more are yet to be identified. Once the active components are identified 
and a proper biochemical basis of their action is defined, these components may be used 
even for newer purposes (Chakraborty et al., 2009). 
The way in which biological products are produced, controlled and administered requires 
necessary precautions. Unlike conventional pharmaceutical products, which are normally 
produced and controlled using reproducible chemical and physical techniques, biological 
products are manufactured by methods involving biological processes and materials, such 
as cultivation of cells or extraction of material from living organisms. These processes 
display inherent variability, so that the range and nature of by-products are also variable. 
This variability, commercially termed as batch variation, occurs to a higher degree in 
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products of plant origin compared to those of animal origin. Thus in the manufacture of 
biological products for direct application to human, full adherence to GMP (Good Medical 
Practice) is necessary for all production steps, beginning with the starting material from 
which the active ingredients are produced (WHO, 1992). 
For any drug to make its mark in the international market, certification from regulatory 
authority to ensure its safe use without side effects is compulsory. Exhaustive research to 
verify the pharmacological efficacy of the drugs derived from traditional medicine in 
pharmaceutical and biomedical arena is necessary. This would enable to confirm with 
ancient texts and to understand and verify how the specific pharmacological action of the 
drug is manifested. Research on the extract reveals ample opportunity for discovery of 
potent bioactive components whose precise mechanism of action is yet to be elucidated. In 
the present era of modern pharmaceutical and biomedical research, it has become necessary 
to verify the pharmacological effects of the drugs in order to check whether they correspond 
to the ancient texts and to study how the drugs work, and also to isolate the active 
principles that result in the specific pharmacological action of the extract. In this review, we 
aim to discuss the efficacy and the biochemical components present in the aqueous extract 
of human placenta, which has potent wound healing attributes. 
2. Preparations of human placental extract      
Placental extracts can be classified into two different types: aqueous extract and hydroalcoholic 
extract. The components present in the extract depend on the method of its preparation and 
are based on solubility of the components in respective solvent of extraction. Thus, an aqueous 
extract is likely to contain more polar molecules such as peptides/proteins, small organic 
components like amino acids, nucleotides, polydeoxyribonucleotides (PDRNs), carbohydrates 
and trace amount of lipids mostly bound to proteins which are comparatively soluble in 
aqueous medium. Likewise, various types of lipids may be present in hydroalcoholic extract 
(less polar and hydrophobic). Chemical analysis of the hydroalcoholic extract revealed the 
presence of glycosphingolipids, cholesterol, triglycerides, high density lipoproteins, 
carbohydrates, sialic acids and others, including amino acids, nucleotides, carotenes, vitamins, 
including small amount of low-molecular-weight proteins/peptides containing hydrophobic 
amino acid residues which are soluble in a less polar solvent.  
Modern indigenous aqueous placental extract is prepared employing Filatov’s procedure. 
The manufacturing procedure of the indigenous extract holding confidentiality of the 
proprietary terms is as follows: fresh placentae were stored in ice and portions were tested 
for HIV antibody and Hepatitis B surface antigen. Single hot and cold aqueous extractions 
were done after incubating dissected and minced placenta at 900C and 60C respectively. This 
was followed by sterilization of the extract under saturated steam (pressure 15-lbs/sq inch 
at 1200C for 40 min). After filtration and addition of 1.5% (v/v) benzyl alcohol as 
preservative, ampoules were filled and sterilized once again under the said condition for 20 
min. In the first sterilization, the extended duration of heat treatment essentially completed 
precipitation of a number of macromolecules like proteins. This is apart from adding safety 
margins to the temperature, time or both to destroy most resistant spore-producing species 
like Clostridium tetani. The terminal sterilization step was to maintain sterility of the 
products after they were filled and sealed in ampoules. Each milliliter of the drug was 
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derived from 0.1 g of fresh placenta. A single batch was prepared from the pool of several 
placentae. The trade name of the extract is ‘Placentrex’. Carried over bioactive components 
in the extract depends on the method of its preparation. As the extract is prepared by 
repeated sterilization process, it is expected that it may contain macromolecules in their 
degraded forms together with small bio-organic compounds such as amino acids, peptides, 
small sized polypeptides, nucleotides, small polynucleotide fragments etc. Only those 
molecules that are heat stable and are able to withstand high sterilization pressure will 
remain biologically active. The active components with significant biological activity have 
been discussed later on. Presence of various organic components gives the extract a 
yellowish tinge (Datta and Bhattacharyya, 2004a).  
In India, several studies have been made on the drug used as wound healer. The extract is a 
potent biogenous stimulator and abundantly used as an efficient wound healer (Punshi, 
1981). Broadly speaking, an aqueous extract of human placenta has the following actions in 
the body: it accelerates cellular metabolism providing the energy for the inflammatory 
response to occur. It also aids in absorption of exudates by controlling its formation, 
removal of unhealthy tissue by debridement and management of bacterial load that are 
required for good wound bed preparation (Hong et al., 2010). It stimulates tissue 
regeneration processes. Aqueous extract of placenta contain nucleotides like PDRNs and 
NADPH that are known for their regeneration effect (Nelson and Cox, 2000). In addition, it 
also supplements growth factors and small peptides that help in matrix formation and cell 
adhesion, thereby promoting wound healing as described in details later on.   
The hydroalcolic extract of placenta is more effective for the treatment of vitiligo. The 
method of preparation of a hydroalcoholic extract of fresh human placenta meant for vitiligo 
treatment has been reported earlier (Pal et al., 1995). Such an extract from human placenta 
with efficient skin pigmenting activity has been developed based on experimental therapies. 
Glycosphingolipids, capable of inducing adhesion, spreading and motility of melanoma is 
present in the extract and therefore, may lead to skin pigmentation through induction of 
melanocytes (Pal et al., 2002). 
3. Role of placental extract in wound healing  
Wound healing is a very complex process that includes inflammation, cell migration, 
extracellular matrix deposition and cell maturation (Diegelmann and Evans, 2004). Several 
cytokines and growth factors are involved in inducing different cell types for healing. 
Extracellular matrixes such as collagen, laminin, and fibronectin are deposited in the dermis 
under the effects of fibroblasts in the later phase of healing. In the last phase, contraction of 
the dermis in full-thickness wounds and squamous differentiation of the keratinocytes on 
the surface of wounds concludes its maturation (Falanga, 2001). Among all the extracts of 
placenta that have been prepared, only the aqueous extract has been shown to have potent 
clinical efficacy in terms of healing. Aqueous extract from placenta is used as a licensed drug 
for wound healing under different trade names in India and overseas countries (Datta and 
Bhattacharyya, 2004a). This could be due the fact that the aqueous extract is a rich source of 
various bioactive peptides with tissue regeneration potential (Chakraborty and 
Bhattacharyya, 2005a; De et al., 2009). In addition, the extract also retains amino acids, 
nucleotides, polydeoxyribonucleotides and carbohydrates that might be responsible for 
wound healing. Most of the wound healers that are available in the market have anti-
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microbial (antibacterial or antifungal) properties but the potency of the extract lies in the fact 
that it not only reduces the inflammatory phase and microbial burden on the wound 
(Chakraborty and Bhattacharyya 2005b) but also help in cell migration (Gupta and 
Chottopadhyay, 2008), matrix formation and tissue regeneration thereby ensuring 
sequential uninterrupted healing. Placental extract plays a beneficial role as a topical agent 
in the management of chronic non-healing wounds. It is reported that the extract promotes 
fibrogenesis, neoangiogenesis and epithelialisation (Shukla et al., 2004). Globally, the extract 
is now accepted as an effective healer in burn injuries, chronic non-healing wounds, post 
surgical dressings, as well as bedsores (Chakraborty et al., 2009).  
Clinical evaluation of the aqueous extract revealed that it has anti-inflammatory and anti-
platelet aggregation activity. As reported the extract exhibits anti-inflammatory response 
probably either through inhibition/inactivation of chemical mediators or by directly 
modulating prostaglandin (PG) production by suppression of cyclooxygenase (COX). 
Kinins, chemical mediators of nonimmunological type of inflammation, have two 
membrane receptor B1 and B2, for their activities. It has been reported that in cotton pellet 
induced subacute inflammation model, the extract may act as inhibitor of the B1-receptor 
thereby exerting its anti-inflammatory effect. It also helps in activation of the clotting 
cascade by trauma which results in platelet activation, followed by aggregation. The clinical 
study of platelet aggregation reflects that this extract can either inhibit PGs synthesis 
pathway or 5-hydroxytryptamine (5-HT) release. In addition, an aqueous extract of human 
placenta has also shown to stimulate collagen synthesis in vivo in rats. The significant 
increase in tensile strength and tissue DNA in the animals given the extract (intra muscular) 
indicates it was associated with marked collagen synthesis. The cytoplasmic repairment was 
revealed from regeneration of protein in appreciable amount. The efficiency of formation of 
collagen depends mainly on the synthesis of hydroxyproline, which was also shown to be 
appreciably high in the i.m. treated rats with the extract. These evidences, as reported, were 
further supported by pictures of histopathological changes showing maximum 
accumulation of collagen fibrils and epithelialisation (Biswas et al., 2001). 
Human and animal models show that placental extract has an immunostimulating action 
both at cellular and humoral levels. It probably increases IgG and IgM at the humoral level 
and total lymphokines at the cellular level. It also reports several advantages over antibiotics 
and chemotherapeutic agents in terms of antibacterial activity including vascularisation of 
wound environment and is free from side effects (Chakraborty et al., 2009). 
The injectable form of placental extract was found to be very effective, inexpensive and 
excellent stimulant of granulation tissue, which is superior to the dressing of povidone 
iodine (Pati et al., 2001). Human placental dressing was found to be effective in clinical 
wound healing for chronic varicose ulcers (Burgos et al., 1989). Later, this finding was 
supported by Subramanian et al., 1990. The wound healing potency of the aqueous extract 
of placenta is thus clinically well established and a lot of evidences support these findings. 
However, the active components present and the molecular mechanisms that are involved 
in the healing process are yet to be defined.  The variety of biological actions of aqueous 
extract of human placenta is a matter of increasing interest. Characterization of such extract 
by isolating the active components present in it and to determine their mechanism of action 
related to wound healing process is of utmost requirement. This is because scientific 
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assessment of such extract is necessary for its better acceptance in medical practice with a 
more convincing approach.  
4. Biochemical characterization and possible mechanism of action of the 
extract  
Human placental extract manufactured by a proprietary extraction method using term 
human placenta as a raw material has potent therapeutic efficacy. Use of placental extract in 
different preparations under various trade names is a recommended worldwide practice. 
Developed from folk knowledge, the aqueous extract is used as a globally accepted licensed 
drug in post surgical dressings, as a healer in burn injuries and chronic wounds under 
different trade name in many countries including India (Chakraborty et al., 2009). 
Isolating active components present in a biological extract is a natural propagation towards 
characterization of the drug. The contents present in the extract depend on the method of its 
preparation. An aqueous extract of placenta contains amino acids, peptides, 
glycosaminoglycans, lipids, polynucleotides (mainly polydeoxyribonucleotide fragments), 
vitamins, minerals etc. Some of them can be chemically or biologically synthesized but 
many of them can only be obtained by isolating them from a natural source. An aqueous 
extract of human placenta of potent therapeutic value is under research in terms of 
identifying the active components present and the biochemical basis of its mode of action. It 
was initiated at Indian Institute of Chemical Biology, Kolkata, India from 1999 and is still 
ongoing. The drug ‘Placentrex’ – manufactured by Albert David Ltd., Kolkata has been used 
for this purpose, which is used as wound healer from long back. The extract is prepared 
under relatively harsh conditions; as a result of which macromolecules are degraded 
generating low molecular weight bio-organic compounds e.g. amino acids, peptides, small 
sized polypeptides, nucleotides, small polynucleotide fragments etc. Owing to the presence 
of PDRNs, the spectral pattern of the extract corresponds mostly to that of DNA with a high 
absorption at 260 nm. Characterization of such extract by isolating the active components 
present in it and to determine their mechanism of action related to wound healing would be 
significant.   
Major findings with its constituents include demonstration of minimal batch variation of the 
extract using conventional spectroscopic and chromatographic techniques like UV-VIS 
absorption spectra, FT-IR, TLC, HPTLC and HPLC and also by newly developed method for 
fingerprinting of multi-component drugs using fluorescence Excitation-Emission-Matrix 
(EEM) plots. Since there is no fingerprinting technique, which could be applied universally 
to separate different class of components, combination of different modes is used and 
upgradation of finger printing procedures is an active area of present research. Fluorescence 
spectroscopy has versatile application in chemistry and biochemistry. Modern versions of 
spectrofluorimeters are equipped with generation of three dimensional (3D) contour plots, 
also called EEM plots. where the z-axis represents emission intensity. Its advantage lies on 
presentation of chromophores having different excitation and emission patterns in a single 
profile. In analytical chemistry, it is frequently used in environmental and hydrological 
studies. Moreover, since wide excitation and emission zones are covered in a single profile, 
there is no scope of missing any newly emerged fluorophore in a batch. This safeguard is 
almost impossible to include in two-dimensional fluorescence emission profiles. A high 
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degree of consistency between different batches of the drug was observed from EEM. 
Validity of these results from EEM was crosschecked by different spectroscopic and 
chromatographic modes (Datta and Bhattacharyya, 2004b). This consistency reflects 
standardization of the manufacturing process of the drug and also adherence of uniform 
placental composition irrespective of the nutritional status of mothers. Fluorescence 
spectroscopy has been shown to have capability of identifying the fluorophores in a 
complex multi-component biological system.  
During characterization of the extract, a fluorophore has been detected which had excitation 
and emission properties similar to nicotinamide adenine dinucleotide, reduced form 
(NADH) and nicotinamide adenine dinucleotide phosphate, reduced form (NADPH). When 
excited at 340 nm, it results in fluorescence emission having maxima around 436 nm, which 
is fairly specific for NADH and NADPH. These are natural constituents of placenta and play 
important roles in different metabolic pathways including wound healing. NAD/NADH 
and NADP/NADPH are major redox-active ‘electron storage’ compounds. One or both of 
these ‘redox pairs’ is involved in every major biochemical pathway. They participate in the 
trafficking of electrons as ‘reducing equivalents,’ the electron packets that facilitate 
metabolism. Evidence of only free and bound NADPH (supplying as a substrate or cofactor 
for enzymes) were demonstrated using thin layer chromatography and reversed-phase 
HPLC. Since NADPH is known to regulate a number of phenomena related to wound 
healing, we have investigated its presence in different batches of the drug. Biological 
functionality of the fluorophore in the extract has been confirmed by enzymatic assay. It has 
been shown that NADPH in aging human skin cells increases synthesis of collagen 
involving filaggrin and keratin in vitro (Datta and Bhattacharyya 2004a). 
The extract also has the ability for in vitro NO induction in mouse peritoneal macrophage 
and human peripheral blood mononuclear cells (PBMC). The aqueous extract has been 
investigated in terms of induction of NO by macrophages. It has been demonstrated that 
with an increase of NO production, concomitant decrease in NADPH present in the applied 
placental extract was observed, thereby indicating that the NADPH pool of placental extract 
is metabolized, further justifying the biological potency of this nucleotide in the extract 
(Chakraborty et al., 2006). It has been well documented that nitric oxide (NO) has multiple 
effects at the molecular, cellular and physiological level in wound healing. It promotes 
inflammatory mediation of repair mechanism and wound matrix development followed by 
remodeling. NO mediated cellular signaling possibly enhances wound repair by increasing 
tissue oxygen availability through angiogenesis. It is produced in macrophages by the 
enzyme inducible nitric oxide synthase (iNOS) during wound healing (Luo and Chen, 2005). 
It acts as a biological signaling and effector molecule capable of diffusing across membranes 
and reacting with a variety of targets. Once induced, production of NO within the tissue can 
induce an environment that is toxic to invading microorganism (Efron et al., 2000). It 
promotes inflammatory mediation of repair mechanism and wound matrix development 
followed by remodeling. The extract has also shown to induce interferon- (IFN-) 
production by macrophages (Chakraborty et al., 2006).   
Anti-microbial property of the extract against a large number of pathological microorganisms 
related to prevention of secondary infections to wounds has also been demonstrated. The 
extract has an effective inhibitory role on the growth of different microbes particularly growth 
of clinically isolated bacteria, e.g. E. coli from urine and blood culture and S. aureus from pus 
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cells. Drug resistant strains such as E. coli DH5 Pet-16 AmpR and Pseudomonus aeruginosa 
CamR were also significantly inhibited by the extract. The extract has both bacteriostatic and 
fungistatic activities. Dose-dependent response of the extract was observed. A mixture of 
polydeoxyribonucleotides (PDRNs) appears to be the causative agent. Partial protection of 
the wound from secondary microbial infection is thus indicated. Though the mechanism of 
such growth-inhibitory activities has not been studied, it is predicted that the PDRNs 
present in the extract enter the microbes and interfere with their replication machinery 
(Chakraborty and Bhattacharyya, 2005b). 
An important finding was isolation and purification of a peptide of around 7.4 kDa from the 
extract. Derived partial amino acid sequence from mass spectrometric analysis showed its 
homology with human fibronectin type III. Under nondenaturing condition, it formed 
aggregate, the elution pattern of which was identical to that of fibronectin type III as 
confirmed by reverse-phase HPLC. Immuno-blot of the peptide showed strong cross 
reactivity with reference human fibronectin type III-C. It draws special attention because its 
partial amino acid sequence showed homology with 10th type-III fibronectin peptide that 
also contains the ‘RGD’ signature sequence endowed with cell adhesion properties (Nath 
and Bhattacharyya, 2007). The importance of fibronectin in cutaneous wound healing is well 
documented as a general cell adhesion molecule by promoting the spread of platelets at the 
site of injury. It also helps in the adhesion and migration of neutrophils, monocytes, 
fibroblasts and endothelial cells into the wound region, and the migration of epidermal cells 
through the granulation tissue (Chakraborty and Bhattacharyya, 2005a).  
Considering the importance of peptides in wound healing, the fraction was further 
characterized in terms of regulation of some enzyme activities related to repair mechanism. 
Primary investigation revealed that the drug stabilizes some serine proteases against their 
autodigestion by reversibly inactivating them, which enhances the efficiency of proteolytic 
enzymes thereby facilitates wound healing. Further it has been demonstrated that one or more 
peptides from human placental extract including fibronectin type III stabilize trypsin activity 
after strong association, which is reversible in nature. In presence of excess substrate, the 
conjugate is dissociated. Regulation of trypsin activity with prevention of autodigestion has 
been demonstrated in De et al, 2011.  
As a working hypothesis, wound healing can be broadly categorized into three overlapping 
phases both in terms of time and space  cleansing or debridement, following which 
proliferation occurs to provide a platform for tissue regeneration and finally differentiation 
occurs. During debridement, extensive ‘hydrolytic activity’ ensures proper cleaning of the 
wounded tissue. The last two stages of healing require extensive ‘synthetic activity’ and 
minimal hydrolytic activity. Trypsin and similar proteolytic enzymes help in debridement and 
prevent keloid formation during wound healing and therefore regulation of its activity is an 
important criterion. Trypsin, chymotrypsin, collagenase, papain, bromelein etc were reported 
to be effective in wound healing as a debriding agent. These agents remove foreign bodies and 
necrotic tissues and reveals healthy, bleeding tissues so that the wound can heal (Buck and 
Phillips, 1970; Craig, 1975; Ramundo and Gray, 2009). Thus, it is expected that the peptide 
would have greater half-lives in the blood, as serine proteases form a major part of blood 
proteases. Proportionate mixing of ‘Placentrex’ with some proteolytic enzymes and subsequent 
evaluation of its efficacy in wound healing, may be another promising avenue of the future 
study leading to the development of an effective wound healer with debridement potential. 
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It remains questionable whether the proteins and peptides of the drug remain stable in 
human blood as the blood contains many proteases. There is an array of proteases in blood, 
which include thrombin, plasmin, Hageman factor, blood coagulation cascade enzymes etc. 
Though it is well known that blood proteases are quite specific about their substrates, the 
question of stability of the drug components remains an important issue from clinical point 
of view. It has been demonstrated by size exclusion HPLC that the peptide fraction of the 
drug remains unaffected in presence of plasma and serum proteases from human blood 
(Fig. 1). In reverse, it has also been demonstrated by gelatin zymography that the blood 
proteases remain unaffected after incubation for 48 hrs in presence of the placental peptide 
fraction (Fig. 2). However, protease-substrate interactions are not always guided by the 
specificity of the protease. One essential requirement for proteolysis is that the hydrolysable 
bond must be physically accessible to the catalytic site of the protease. Often proteins can 
survive proteolysis out of its compact globular structures under physiological conditions in 
presence of proteases. It is generally observed that any drug administered through intra 
venous or intra muscular remains active in circulation for a maximum period of 48 hours 
after which it is removed from circulation by metabolism or excretion. Thus the studies were 
restricted within 48 hrs.  
 
Fig. 1. Stability of the peptide fraction from placental extract in presence of blood protease 
(plasma) over 48 hr as observed from size exclusion HPLC using Waters Protein Pak 125 
column (fractionation range 2-20 kDa). The sharp major peak corresponds to the unresolved 
peptide fractions of Mw 10-16 kDa while the second peak corresponds to elution of small 
bioorganic molecules. The overlapping profiles from top to bottom indicate samples of 
incubation time 0, 6, 18, 24, 48 hr respectively at 37°C. The loss of intensity appears to be due 
to partial precipitation of the peptides removed by centrifugation though there is no 
indication of multimer formation at the void volume of the column. The downward arrow 























Fig. 2. Stability of blood proteases in presence of peptide fraction of human placental extract 
as observed by gelatin zymography. (A) Representing trypsin 0.75 ng (lane 1), buffer as 
control (lane 2), serum isolated from blood (lane 3) and plasma (lane 4), both were incubated 
for 48 hr with 10 µg/ml of peptide fraction of the placental extract. (B) Human serum (lane 1) 
and plasma (lane 2) as control. 
As a part of the healing process, the body enters a hypermetabolic phase, where there is an 
increase in demand for carbohydrates. Cellular activity is fuelled by adenosine triphosphate 
(ATP), which is derived from glucose, providing the energy for the inflammatory response 
to occur. In addition to their role in metabolic process, carbohydrates are involved in cellular 
signaling as well as cell-cell interaction. While addressing roles of carbohydrates, interaction 
of lysozyme with the extract was investigated. The enzyme showed positive reactivity in a 
time and concentration dependent manner indicating that carbohydrate residues were 
present. Attempts are in progress to identify these residues by GC-MS in presence of 
reference sugars (unpublished observation).     
        1                  2              3               4 
A B 
         1              2 
www.intechopen.com
 
Placental Extract as a Therapeutic Agent 
 
87 
This multifaceted character of the drug encourages further investigation following which 
the biochemical basis of its mode of action is likely to be highlighted. 
5. Multiple therapeutic properties of aqueous extract of human placenta 
Several clinical investigations and findings have been reported on effective therapeutic use 
of placental extract such as clinical evaluation in radiation-induced oral mucositis (Kaushal 
et al., 2001), restorative effects in X-ray-irradiated mice (Mochizuki and Kada, 1982), for the 
treatment of myopic and senile chorio-retinal dystrophies (Girotto and Malinverni, 1982), 
rheumatic arthritis (Rosenthal, 1982), osteoarthritis (Kim et al, 2010), skin diseases (Punshi, 
1981), for prevention of recurring respiratory infections (Lo Polito, 1980), in the therapy of 
urticarias (Mittal, 1977), in therapy of children with asthmatic bronchitis (Vecchi et al., 1977), 
in atrophic rhinitis (Sinha et al, 1976), on hepatic drug metabolizing enzymes (Bishayee et 
al., 1995), in cerebral arteriosclerosis (Lafay 1965), in periodontal disease (Calvarano et al., 
1989). Topical treatment of cervico-vaginal lesions using a placental extract with 
anticomplement activity (Sgro, 1978), local therapy of psoriasis (Lodi et al., 1986), treatment 
of vitiligo with topical melagenine (Suite and Quamina, 1991) has also been reported to be 
successful. A number of reports have been found on placental extract effective in arthritis 
(Yeom et al., 2003). Effectiveness of topical application of polydeoxiribonucleotide from 
human placenta in gynaecology has been documented (Bertone and Sgro, 1982). Post-
irradiation cystitis improved by instillation of early placental extract in saline (Mićić and 
Genbacev, 1988) and placental extract injections in the treatment of loss of hair in women is 
also documented (Hauser, 1982). It was reported that aqueous human placental extract 
induced potentiation of morphine antinociception may have a clinical significance for the 
treatment of persistent or chronic pain (Gurgel et al., 2000). Clinical evaluation of the 
aqueous extract has shown that the drug acts as a potent wound healer with anti 
inflammatory and immunotropic effect. Placental extract has long been used as a cosmetic 
supplement for skin care and skin pigmentation (Pal et al., 2002). Recently it has been 
reported that menopausal symptoms and fatigue in middle-aged women improved after the 
treatment with the aqueous placental extract (Kong et al., 2008). It has been reported that an 
aqueous extract of human placenta was found to offer protection against established 
experimental visceral leishmaniasis in BALB/c mice and hamsters, whether the Leishmania 
donovani strain involved was one that was sensitive or resistant to pentavalent antimony. 
Based on the results of this pilot study, a further evaluation of the efficacy of human 
placental extract therapy, which may offer a cost-effective way of improving the treatment 
of antimony-resistant cases of visceral leishmaniasis, is being undertaken (Chakraborty et 
al., 2008).  
Several studies have shown therapeutic use of other animal placenta also. Recent report 
shows that the protective effect of porcine placental extract in contact hypersensitivity is 
mediated by inhibition of the inflammatory responses and IgE production to modulate skin 
inflammation (Jash et al., 2011). Cow placental extract efficiently accelerates cell division and 
growth factor expression by raising the insulin-like growth factor (IGF-1) mRNA and 
protein level to increase hair follicle size and hair length in murine (Zhang et al., 2011). 
Bovine placental extract is capable of improving the tenderness of certain injuries that are 
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relatively high in connective tissue, while avoiding myofibrillar protein hydrolysis (Phillips 
et al. 2000). An immunomodulatory peptide was isolated from aqueous extract of bovine 
placenta which showed no significant homology with other immunomodulatory peptides 
(Fang et al., 2007). Thus, the therapeutic potency of placental extract has earned global 
recognition. 
6. Conclusion 
Natural medicine continues to play an important role for prevention, alleviation and cure of 
diseases. In some part of the Western world, the use of traditional medicine has been largely 
lost. However, it is a widespread phenomenon in the developing countries where 80% of 
the population is still relying on traditional medicine for primary healthcare. Derived 
from folklore, human placental preparations show immense therapeutic value and can be 
safely used once it is ensured that the source is free from fatal infections like HIV, HBV, 
HCV and alike. The aqueous extract of human placenta is a scientifically proven potent 
wound healer. Characterization of active components present in different placental 
preparations and correlating them with their therapeutic actions are the promising avenue 
for future study. A fibronectin type III-like peptide present in the aqueous extract appears 
to be one of the key components for wound healing. It is known from the literature that 
this type of peptide inhibits tumor growth, angiogenesis and metastasis. Therefore, future 
work should include evaluation of human placental extract as anti-tumor agent. 
Identification of the possible signaling pathways for wound healing as well as other 
therapeutic properties of the placental peptide should receive immediate attention. 
Additional components identified include PDRN and NADPH. Further, yet unidentified 
peptides or small molecules might also be present in various preparations of the extract 
that might play roles in wound healing and related disorders. Identification of other 
biologically active components in the extract and their mechanism of action in terms of 
cellular signaling, which play significant role in wound healing also needs to be 
addressed.  
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